Astrazeneca (AZN) Other Non-Current Assets (2011 - 2025)
Astrazeneca (AZN) posted quarterly Other Non-Current Assets of $559.0 million for Q4 2025, up 57.02% year-over-year from $356.0 million in Q4 2024, and up 57.02% quarter-over-quarter from $356.0 million in Q4 2024.
Astrazeneca (AZN) Other Non-Current Assets (2011 - 2025) Analysis & Trends
Astrazeneca's Other Non-Current Assets history runs 11 years deep, the most recent figure standing at $559.0 million for Q4 2025.
- In Q4 2025, Other Non-Current Assets rose 57.02% year-over-year to $559.0 million; the TTM figure through Dec 2025 stood at $559.0 million (up 57.02% YoY), while the FY2025 annual figure was $559.0 million, up 57.02% from the prior year.
- Other Non-Current Assets for Q4 2025 stood at $559.0 million, up from $356.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $559.0 million in Q4 2025, with the low at -$447.0 million in Q1 2021.
- The 5-year median for Other Non-Current Assets is $315.0 million (2023), against an average of $229.3 million.
- The sharpest annual moves came in 2021 and 2025: Other Non-Current Assets sank 557.47% in 2021, then soared 57.02% in 2025.
- Astrazeneca's Other Non-Current Assets stood at $391.0 million in 2021, then slumped by 37.85% to $243.0 million in 2022, then rose by 12.76% to $274.0 million in 2023, then climbed by 29.93% to $356.0 million in 2024, then jumped by 57.02% to $559.0 million in 2025.
- Business Quant data shows AZN's Other Non-Current Assets at $559.0 million in Q4 2025, $356.0 million in Q4 2024, and $274.0 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 14.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 10.73 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 19.60 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 5.93 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 12.98 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 4.75 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 9.94 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 3.56 Bn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | 5.50 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 559.00 Mn |
| Dec 31, 2024 | 356.00 Mn |
| Dec 31, 2023 | 274.00 Mn |
| Dec 31, 2022 | 243.00 Mn |
| Dec 31, 2021 | 391.00 Mn |
| Mar 31, 2021 | -447.00 Mn |
| Dec 31, 2020 | 395.00 Mn |
| Mar 31, 2020 | 97.71 Mn |
| Dec 31, 2019 | 53.02 Mn |
| Dec 31, 2018 | 743.98 Mn |
| Dec 31, 2017 | 702.00 Mn |
| Sep 30, 2016 | 254.68 Mn |
| Jun 30, 2011 | 517.00 Mn |